Table 1.
Characteristics of the study population by gender and vertebral fracture
| Characteristics |
Men (n = 892) |
Women (n = 1240) |
||||
|---|---|---|---|---|---|---|
| No vertebral fracture (n = 771) | Vertebral fracture (n = 121) | P | No vertebral fracture (n = 1079) | Vertebral fracture (n = 161) | P | |
| Age (years) |
67.4 (7.6) |
70.4 (7.5) |
<0.001 |
67.3 (7.1) |
71.3 (7.6) |
<0.001 |
| Body height (cm) |
175.1 (6.5) |
174.2 (6.9) |
0.182 |
162.1 (6.1) |
160.3 (7.1) |
0.001 |
| Body weight (kg) |
83.9 (12.1) |
82.9 (11.7) |
0.371 |
71.0 (12.4) |
68.8 (12.4) |
0.039 |
| Hip bone mineral density (BMD) (g/cm2)a |
1.027 (0.142) |
0.973 (0.161) |
<0.001 |
0.901 (0.130) |
0.830 (0.115) |
<0.001 |
| Smoking |
|
|
0.491 |
|
|
0.421 |
| Current |
13.6% (105) |
17.4% (21) |
|
17.5% (189) |
19.3% (31) |
|
| Past |
61.6% (753) |
57.0% (69) |
|
41.5% (448) |
36.0% (58) |
|
| Never |
24.8% (191) |
25.6% (31) |
|
41.0% (443) |
44.7% (72) |
|
| Physical inactivityb |
20.4% (141) |
17.4% (19) |
0.661 |
19.7% (181) |
18.8% (26) |
0.947 |
| Cardiovascular diseasec |
22.6% (174) |
24.0% (29) |
0.733 |
10.1% (109) |
15.5% (25) |
0.038 |
| Lung diseased |
11.2% (86) |
18.2% (22) |
0.028 |
14.8% (160) |
12.4% (20) |
0.421 |
| Hormone drugs for menopausee |
|
|
|
7.7% (76) |
4.6% (6) |
0.193 |
| Corticosteroid use |
5.8% (45) |
11.6% (14) |
0.018 |
8.3% (90) |
9.3% (15) |
0.678 |
| FVC (liter (SE)) |
4.20 (0.81) |
4.00 (0.86) |
0.014 |
2.95 (0.56) |
2.77 (0.64) |
<0.001 |
| FEV1 (liter (SE)) |
3.05 (0.70) |
2.82 (0.79) |
0.001 |
2.18 (0.48) |
2.02 (0.55) |
<0.001 |
| FEV1/FVC (% (SD)) | 72.5 (8.7) | 69.9 (10.5) | 0.003 | 73.8 (7.4) | 72.5 (8.4) | 0.046 |
The Tromsø Study 2007-08.
Values are mean (SD) or % (n).
an = 860 men and 1152 women.
bn = 799 men and 1057 women.
cCerebral stroke, myocardial infarction, or angina pectoris.
dAsthma, chronic bronchitis, emphysema, or COPD.
en = 1112 women.